Impact of insulin-like growth factor-1 receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer

Gastric Cancer

Volumn 20, Issue 2, 2017, Pages 263-273

  Ichikawa, Wataru ^a   Terashima, Masanori ^b   Ochiai, Atsushi ^c   Kitada, Koji ^d   Kurahashi, Issei ^e   Sakuramoto, Shinichi ^f   Katai, Hitoshi ^g   Sano, Takeshi ^h   Imamura, Hiroshi ⁱ   Sasako, Mitsuru ^j  

^a SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^b SHIZUOKA CANCER CENTER   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION FUKUYAMA MEDICAL CENTER   (Japan)

^e IAnalysis LLC   (Japan)

^f SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^g NATIONAL CANCER CENTER HOSPITAL   (Japan)

^h CANCER INSTITUTE HOSPITAL   (Japan)

ⁱ TOYONAKA MUNICIPAL HOSPITAL   (Japan)

^j HYOGO COLLEGE OF MEDICINE   (Japan)

more..

Author keywords

ACTS GC study; AREG; Gastric cancer; IGF1R

Indexed keywords

AMPHIREGULIN; FORMALDEHYDE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PARAFFIN; SOMATOMEDIN C RECEPTOR; TUMOR MARKER; ANTINEOPLASTIC ANTIMETABOLITE; AREG PROTEIN, HUMAN; DRUG COMBINATION; IGF1R PROTEIN, HUMAN; MESSENGER RNA; OTERACIL; S 1 (COMBINATION); SOMATOMEDIN RECEPTOR; TEGAFUR;

ABCB1GENE; ABCC1 GENE; ACTB GENE; ADJUVANT THERAPY; ADULT; AGED; ANGPT2 GENE; APC GENE; AREG GENE; ARTICLE; BAX GENE; BCL2 GENE; BCL2L11 GENE; CANCER STAGING; CANCER SURVIVAL; CAV1 GENE; CONTROLLED STUDY; DAPK1 GENE; DHFR GENE; DPYD GENE; DUT GENE; E2F1 GENE; EGFR GENE; ERBB2 GENE; ERCC1 GENE; EREG GENE; ESR1 GENE; EZH2 GENE; FAS GENE; FEMALE; FPGS GENE; GADD45A GENE; GAPDH GENE; GENE; GENE EXPRESSION; GGH GENE; GZMA GENE; HDAC1 GENE; HPSE GENE; HUMAN; HUMAN TISSUE; IGF1R GENE; INTERMETHOD COMPARISON; ITGB3 GENE; LDHA GENE; LRP5 GENE; MAJOR CLINICAL STUDY; MALE; MAPT GENE; MGMT GENE; MLH1 GENE; MTHFR GENE; MUC2 GENE; OVERALL SURVIVAL; PATHOGENESIS; PECAM1 GENE; PLA2G2A GENE; PLAU GENE; PTEN GENE; PTGS2 GENE; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; REG4 GENE; RETROSPECTIVE STUDY; RPLP0 GENE; RRM1 GENE; RRM2 GENE; RUNX3 GENE; SPARC GENE; STOMACH CANCER; TGFA GENE; THBS1 GENE; TOP1 GENE; TOP2A GENE; TREATMENT OUTCOME; TYMP GENE; TYMS GENE; UMPS GENE; UPP1 GENE; VCAM1 GENE; VEGFA GENE; VERY ELDERLY; ADJUVANT CHEMOTHERAPY; DRUG COMBINATION; FOLLOW UP; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; AMPHIREGULIN; ANTIMETABOLITES, ANTINEOPLASTIC; BIOMARKERS, TUMOR; CHEMOTHERAPY, ADJUVANT; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, SOMATOMEDIN; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR;

EID: 84958770370     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-016-0600-x     Document Type: Article

References (31)

1. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7:548–57.
2. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.
3. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II/III gastric cancer: ACTS-GC. J Clin Oncol. 2011;29:4387–93.
4. Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S, et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res. 2012;18:5992–6000.
5. Sasako M, Terashima M, Ichikawa W, Ochiai A, Kitada K, Kurahashi I, et al. Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer. Gastric Cancer. 2015;18:538–48.
6. Fareed KR, Kaye P, Soomro IN, Ilyas M, Martin S, Parsons SL, Madhusudan S. Biomarkers of response to therapy in oesophago-gastric cancer. Gut. 2009;58:127–143.
7. Ichikawa W. Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway. Gastric Cancer. 2006;9(3):145–55.
8. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97:1180–4.
9. Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol. 2006;17:1818–25.
10. Bonanomi A, Kojic D, Giger B, Rickenbach Z, Jean-Richard-Dit-Bressel L, Berger C, et al. Quantitative cytokine gene expression in human tonsils at excision and during histoculture assessed by standardized and calibrated real-time PCR and novel data processing. J Immunol Methods. 2003;283:27–43.
11. Pérez S, Royo LJ, Astudillo A, Escudero D, Alvarez F, Rodríguez A, et al. Identifying the most suitable endogenous control for determining gene expression in hearts from organ donors. BMC Mol Biol. 2007;8:114.
12. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034.
13. Lee J, Sohn I, Do IG, Kim KM, Park SH, Park JO, et al. Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery. PLoS One. 2014;9(3):e90133.
14. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4:505–18.
15. Li R, Pourpak A, Morris SW. Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem. 2009;52:4981–5004.
16. Ludovini V, Bellezza G, Pistola L, Bianconi F, Di Carlo L, Sidoni A, et al. High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol. 2009;20:842–9.
17. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res. 2008;14:6364–70.
18. Liao Y, Abel U, Grobholz R, Hermani A, Trojan L, Angel P, et al. Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade. Hum Pathol. 2005;36:1186–96.
19. Mountzios G, Kostopoulos I, Kotoula V, Sfakianaki I, Fountzilas E, Markou K, et al. Insulin-like growth factor 1 receptor (IGF1R) expression and survival in operable squamous-cell laryngeal cancer. PLoS One. 2013;8:e54048.
20. Djavan B, Waldert M, Seitz C, Marberger M. Insulin-like growth factors and prostate cancer. World J Urol. 2001;19:225–33.
21. Cappuzzo F, Tallini G, Finocchiaro G, Wilson RS, Ligorio C, et al. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Ann Oncol. 2010;21:562–7.
22. Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, et al. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol 2010;28:2174–2180.
23. Cappuzzo F, Toschi L, Tallini G, Ceresoli GL, Domenichini I, Bartolini S, et al. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol. 2006;17:1120–7.
24. Jiang Y, Wang L, Gong W, Wei D, Le X, Yao J, et al. A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis. 2004;21:755–64.
25. Matsubara J, Yamada Y, Nakajima TE, Kato K, Hamaguchi T, Shirao K, et al. Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer. Oncology. 2008;74:76–83.
26. Di Fiore PP, Segatto O, Taylor WG, Aaronson SA, Pierce JH. EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling. Science. 1990;248(4951):79–83.
27. Wells A. EGF receptor. Int J Biochem Cell Biol. 1999;31(6):637–43.
28. Tabernero J, Cervantes A, Rivera F, Martinelli E, Rojo F, von Heydebreck A, et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol. 2010;28(7):1181–9.
29. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25(22):3230–7.
30. Stahler A, Heinemann V, Giessen-Jung C, Crispin A, Schalhorn A, Stintzing S, et al. Influence of mRNA expression of epiregulin (EREG) and amphiregulin (AREG) on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial). Int J Cancer 2015;138:739–46.
31. Addison CL, Ding K, Zhao H, Le Maître A, Goss GD, Seymour L, et al. Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR. 21. J Clin Oncol 2010;28:5247–56.